"Expansion of our company to the Detroit area allows Pico-Tesla to ramp-up patient enrollment for our ongoing Phase III clinical study of Magneceutical™ Therapy in Parkinson's disease patients," said Allen Braswell, CEO of Pico-Tesla. "The addition of Detroit and Clearwater gives us three clinics that are now involved in our pivotal trial in Parkinson's Disease. With IRB approval in hand, we look forward to commencing patient enrollment in the Detroit area, with the help of the Detroit Clinical Research Center (DCRC), a well-known CRO (clinical research organization) in the Midwest."
The purpose of the ongoing Phase III clinical trial is to demonstrate the efficacy of Magneceutical™ Therapy as an adjunctive therapy to improving aspects of health and quality of life that are relevant to patients with Parkinson's Disease. Pico-Tesla intends to submit the Phase III data and analysis via a 510(k) de novo application to obtain FDA clearance to sell the device in the United States. The Phase III clinical trial was designed by principal investigator Rajeev Kumar, M.D., a movement disorder specialist and medical director of the Colorado Neurological Institute Movement Disorder Center, Englewood, Colo.
Pico-Tesla's Magneceutical™ Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device-the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols-intended to improve a number of the signs and symptoms of Parkinson's and other diseases, including atrial fibrillation, Alzheimer's disease, fibromyalgia and osteoarthritis.
Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with operations at: 7852 South Elati, Suite #202, Littleton, CO 80120 (303-795-3222); and, 4700 140th Avenue North, Suite #101, Clearwater, FL 33762.
